DYN — Dyne Therapeutics Share News
0.000.00%
Last trade - 00:00Dyne Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP-Alphabet, Domino's Pizza, McKesson
U.S. RESEARCH ROUNDUP-Analog Devices, NVIDIA, Snowflake
U.S. STOCKS ON THE MOVE-Brady Corp, Moderna, crypto shares
U.S. STOCKS ON THE MOVE-Dorian, ChargePoint Holdings, Transcat
U.S. STOCKS ON THE MOVE-Edwards Lifesciences, Petco, Williams-Sonoma
U.S. STOCKS ON THE MOVE-PDD Holdings, Analog Devices, BuzzFeed Inc
Dyne Therapeutics down on pricing of public offering
Brief: Dyne Therapeutics Announces Pricing Of $325.5 Million Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Palo Alto Networks, Micron, Target
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Dyne Therapeutics, AZZ
Dyne Therapeutics jumps on positive data for muscle disorder drugs
Brief: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) To Newly Appointed President And Chief Executive Officer
Dyne slides after appointing new CEO
Brief: Dyne Therapeutics Names Former Bioverativ Executive John Cox As New CEO
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Dyne Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Stifel says Avidity trial update is 'positive' for muscle wasting treatments
Dyne Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview